- $53.92m
- $139.59m
- $87.69m
- 41
- 75
- 87
- 75
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 4.47 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.44 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 3.64 | ||
| Price to Sales | 0.57 | ||
| EV to EBITDA | 13.37 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -3.71% | ||
| Return on Equity | -127.13% | ||
| Operating Margin | -5.13% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | 28.51 | 52.39 | 65.44 | 87.69 | 95.08 | 119.1 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cansortium Inc. is a vertically integrated cannabis company with licenses and operations in Florida, Pennsylvania and Texas. The Company operates under the private label, Fluent. The Company, through its subsidiaries, is licensed to produce and sell medical cannabis in Florida and Texas and is licensed to sell medical cannabis in Pennsylvania. The Company’s medical cannabis products are offered in oral drops, capsules, suppositories, topicals, syringes, dried flower, pre-rolls, cartridges and edibles and accessories. The Company’s subsidiaries include Cansortium Holdings LLC, Cansortium Pennsylvania, LLC, Cansortium Puerto Rico, LLC, Cansortium Texas, LLC, Cansortium Canada Holdings Inc., Fluent Servicing, LLC, Cansortium Florida, LLC., Spirit Lake Road Nursery, LLC, Harvest Park Lot 9 Investors LLC, Fluent Hemp LLC and Cansortium Michigan LLC.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- August 31st, 2018
- Public Since
- March 21st, 2019
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
Canadian Securities Exchange- Shares in Issue
- 299,529,367
- Address
- 82 NE 26th St Unit 110, MIAMI, 33137-4442
- Web
- http://cansortium.com/
- Phone
- +1 3059022720
- Contact
- Sean Mansouri
- Auditors
- BAKER TILLY US LLP
Upcoming Events for TIUM.U
Q1 2024 Cansortium Inc Earnings Release
Cansortium Inc Annual Shareholders Meeting
Q2 2024 Cansortium Inc Earnings Release
Similar to TIUM.U
4Front Ventures
Canadian Securities Exchange
Ascend Wellness Holdings
Canadian Securities Exchange
Atlas Global Brands
Canadian Securities Exchange
Ayr Wellness
Canadian Securities Exchange
Braxia Scientific
Canadian Securities Exchange
FAQ
What is the Cansortium share price?
As of Today at 19:04 UTC, shares in Cansortium are trading at $0.18. This share price information is delayed by 15 minutes.
How has the Cansortium share price performed this year?
Shares in Cansortium last closed at $0.18 and the price had moved by +140% over the past 365 days. In terms of relative price strength the Cansortium share price has outperformed the Toronto Stock Exchange 300 Composite Index by +127.74% over the past year.
What are the analyst and broker recommendations for Cansortium?
The overall consensus recommendation for Cansortium is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cansortium dividend yield?
Cansortium does not currently pay a dividend.
Does Cansortium pay a dividend?
Cansortium does not currently pay a dividend.
When does Cansortium next pay dividends?
Cansortium does not currently pay a dividend.
How do I buy Cansortium shares?
To buy shares in Cansortium you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cansortium?
As of the previous close price of $0.18, shares in Cansortium had a market capitalisation of $53.92m.
Where are Cansortium shares listed?
Here are the trading details for Cansortium:
- Country of listing: Canada
- Exchange: CNX
- Ticker Symbol: TIUM.U
What kind of share is Cansortium?
Based on an overall assessment of its quality, value and momentum Cansortium is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cansortium share price forecast for 2024?
The analyst consensus target price for shares in Cansortium is $0.69. That is 284.11% above the last closing price of $0.18.
Analysts covering Cansortium currently have a consensus Earnings Per Share (EPS) forecast of -$0.02 for the next financial year.
What is the trend in the Cansortium share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cansortium. Over the past six months, its share price has outperformed the Toronto Stock Exchange 300 Composite Index by +42.92%.
As of the last closing price of $0.18, shares in Cansortium were trading +47.33% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cansortium PE Ratio?
The Cansortium PE ratio based on its reported earnings over the past 12 months is 4.47. The shares last closed at $0.18.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cansortium?
We do not have data on Cansortium's directors